scispace - formally typeset
P

Pei-Teh Chang

Researcher at National Taiwan University

Publications -  13
Citations -  182

Pei-Teh Chang is an academic researcher from National Taiwan University. The author has contributed to research in topics: Prodrug & Neurite. The author has an hindex of 6, co-authored 13 publications receiving 155 citations.

Papers
More filters
Journal ArticleDOI

Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer’s Disease

TL;DR: In vitro, novel quinazolin-4-one derivatives containing a hydroxamic acid moiety induced neurite outgrowth accompanied by growth-associated protein 43 expression, and they enhanced the synaptic activities of PC12 and SH-SY5Y neuronal cells without producing toxic or mitogenic effects.
Journal ArticleDOI

Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.

TL;DR: This study demonstrates the significance of dual Aurora B/FLT3 inhibitors for the development of potential agents to treat AML by finding that compound 54 is more potent than sunitinib not only against FLT3-WT AML cells but also active against sunit inib-resistant FLT 3-ITD AML Cells.
Journal ArticleDOI

Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor

TL;DR: In A549 cells, 31h decreased phosphorylation of histone H3, triggered polyploidy, induced expression of pro-apoptotic Fas and FasL with subsequent activation of caspase 8, resulting into apoptosis, and 4-Oxo-1,4-dihydropyridine derivatives demonstrated potent in vivo efficacy with a daily dose of 5 mg/kg.
Journal ArticleDOI

Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1,1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors.

TL;DR: Intraperitoneal administration of 30c at 100mg/kg demonstrated potent acute anti-inflammatory activity and benzo[1.3.2]dithiazolium ylide 1,1-dioxide represented a novel scaffold for the exploitation in developing dual COX-2/5-LOX inhibitors.